Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

June 30, 2003

Conditions
Chronic Obstructive Pulmonary DiseaseCOPD
Interventions
DRUG

Roflumilast

Trial Locations (37)

Unknown

ALTANA Pharma, Cities in Alabama

ALTANA Pharma, Cities in Arizona

ALTANA Pharma, Cities in California

ATLANA Pharma, Cities in Colorado

ALTANA Pharma, Cities in Conneticut

ALTANA Pharma, Cities in Delaware

ALTANA Pharma, Cities in Florida

ALTANA Pharma, Cities in Georgia

ALTANA Pharma, Cities in Idaho

ALTANA Pharma, Cities in Indiana

ALTANA Pharma, Cities in Iowa

ALTANA Pharma, Cities in Kansas

ALTANA Pharma, Cities in Kentucky

ALTANA Pharma, Cities in Louisiana

ALTANA Pharma, Cities in Maryland

ALTANA Pharma, Cities in Michigan

ALTANA Pharma, Cities in Missouri

ALTANA Pharma, Cities in Nebraska

ALTANA Pharma, Cities in Nevada

ALTANA Pharma, Cities in New Jersey

ALTANA Pharma, Cities in New York

ALTANA Pharma, Cities in North Carolina

ALTANA Pharma, Cities in Ohio

ALTANA Pharma, Cities in Oregon

ALTANA Pharma, Cities in Pennsylvania

ALTANA Pharma, Cities in Rhode Island

ALTANA Pharma, Cities in South Carolina

ALTANA Pharma, Cities in Texas

ALTANA Pharma, Cities in Utah

ALTANA Pharma, Cities in Virginia

ALTANA Pharma, Cities in Washington

ALTANA Pharma, Cities in West Virginia

ALTANA Pharma, Cities in Argentina

ALTANA Pharma, Cities in Canada

ALTANA Pharma, Cities in Colombia

ALTANA Pharma, Cities in Mexico

ALTANA Pharma, Cities in Peru

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY